innovative drugs
How Hyperinflation Affects the P&MA Strategy of Innovative Drugs

Inflation rates keep increasing in Argentina, making it all the more difficult for manufacturers to design good Pricing and Market Access (P&MA) of innovative medicines.

| Blog | Healthcare & Life Sciences Commercial Strategy & Pricing Consulting
US Health Policy
US Health Policy Update: Important Provisions of the Build Back Better Act

The recent Build Back Better Act presents an opportunity to completely change the healthcare market landscape in the US if certain provisions make it through the Senate.

| Blog | Healthcare & Life Sciences Customer, Product & Market Strategy Pricing Strategy & Revenue Management
pharmaceutical drug prices
Chile: New Laws and Regulations Controlling Pharmaceutical Drug Prices

The CENABAST law and the “Drugs 2” bill will have a serious effect on the Chilean pharmaceutical industry.

| Blog | Healthcare & Life Sciences Customer, Product & Market Strategy Pricing Strategy & Revenue Management
patient access
China Implements Dual-Channel Policy to Improve Patient Access to Drugs

China’s new dual-channel policy will have a serious impact on how manufacturers deal with pharmacies and hospitals in the country.

| Blog | Healthcare & Life Sciences Customer, Product & Market Strategy
optimizing market access
MEB-ZIN Parallel Procedure: Optimizing Market Access in the Netherlands

In this brief we explore the introduction and implications of the MEB-ZIN Parallel Procedure pilot, which was launched in 2019 in the Netherlands.

| Blog | Healthcare & Life Sciences Customer, Product & Market Strategy
innovation drugs Spain
Funding for Early Innovation Drugs Slows Down in Spain

The approval for early innovation products is gaining momentum throughout the EU.

| Blog | Healthcare & Life Sciences Customer, Product & Market Strategy
china commercial health
China Commercial Health Insurance Opportunities

Commercial health insurance (CHI) has an increasingly important role to play in China’s healthcare security system.

| Blog | Healthcare & Life Sciences Customer, Product & Market Strategy
provider based contracting
What Physics Teaches Us About Provider Based Contracting for Pharmaceuticals

The introduction of average sales price based reimbursement (ASP) in 2003, has brought about a challenging landscape for manufacturers of physician-administered medications.

| Blog | Healthcare & Life Sciences Pricing Strategy & Revenue Management
provider reimbursement
Shifts in Provider Reimbursement and How Manufacturers Should Respond

Value-based payments for providers are gaining momentum in the United States.

| Blog | Healthcare & Life Sciences Pricing Strategy & Revenue Management
2022 China MedTech Industry Outlook

We recently released our annual China Medtech Outlook for this year, and highlighted three key trends for the industry.

| Blog | Healthcare & Life Sciences Commercial Strategy & Pricing Consulting
Language
Search